Microbot Medical Advances Commercial Rollout of Robotic System
08.02.2026 - 10:16:04
Microbot Medical has concluded the inaugural commercial showcase of its LIBERTY robotic system at the Society of Interventional Oncology (SIO) annual meeting. The event marks a significant step in the company's phased commercialization strategy, which is currently in a limited market release phase. Attention from investors is now shifting toward upcoming quarterly financial results and the operational scale-up required for a broader launch.
- Current Phase: Limited Market Release (LMR) ongoing
- Full Commercial Launch: Scheduled for April 2026
- Clinical Trial Data: 100% success rate in robotic navigation
- Upcoming Milestone: Quarterly report expected February 24 or 25, 2026
The company's commercial ambitions are supported by clinical outcomes from its ACCESS PVI study. The trial demonstrated not only flawless navigation but also achieved a 92% reduction in radiation exposure for medical staff compared to manual procedures. Furthermore, no device-related complications were reported. A key question for the market is whether this high success rate can be maintained as the system moves into wider clinical use.
Microbot is targeting a substantial addressable market in the United States, estimated at approximately 2.5 million peripheral endovascular procedures annually. Its business model is centered on a single-use, disposable platform. This approach is designed to eliminate the high capital expenditure and complex sterilization processes typically associated with reusable robotic systems in healthcare.
Should investors sell immediately? Or is it worth buying Microbot Medical?
Strategic Commercialization Timeline
The ongoing limited market release, which commenced in late 2025, has seen early adoption by leading institutions, including Emory University Hospital, which has integrated the technology into its radiological programs. Insights gathered from this initial phase are being directly applied to preparations for the next stage of expansion.
The full commercial rollout is strategically planned for April 2026, timed to coincide with the annual meeting of the Society of Interventional Radiology (SIR). The company identifies interventional oncology as a primary value driver within radiology. The LIBERTY system, a remotely controlled disposable robot, aims to reduce both radiation exposure and physical strain for physicians during procedures.
Operational Focus and Investor Outlook
The immediate weeks ahead will be focused on operational execution. Microbot Medical is expected to publish its next quarterly financial report on February 24 or 25, 2026. These figures are anticipated to provide critical insight into the progress of manufacturing and commercial scaling efforts ahead of the planned April launch. The company's ability to successfully manage this transition will be a focal point for market observers assessing its near-term trajectory.
Ad
Microbot Medical Stock: Buy or Sell?! New Microbot Medical Analysis from February 8 delivers the answer:
The latest Microbot Medical figures speak for themselves: Urgent action needed for Microbot Medical investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.
Microbot Medical: Buy or sell? Read more here...
